Status:
COMPLETED
Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
University of Aarhus
Conditions:
Rhinitis, Allergic, Seasonal
Rhinitis; Allergic, With Asthma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The primary goal is to investigate the efficacy of intralymphatic immunotherapy (ILIT) for the treatment of allergic rhinitis and allergic asthma due to sensitisation to grass pollen allergens. 60 pat...
Detailed Description
This study is part of a multicenter trial Phase III that takes place also in Denmark and Sweden (EudraCT registration number 2020-001060-28). The primary goal is to investigate the efficacy of intraly...
Eligibility Criteria
Inclusion
- passed online screening with a Rhinoconjunctivitis Total Symptom Score (RTSS) value of 8 or higher.
- sensitisation to grass pollen allergens with a skin prick test reaction to grass pollen allergen of 3 mm or more.
- eligible to allergen immunotherapy.
- 18 years or older.
- comfortable with digital data entry.
Exclusion
- previous grass pollen-specific immunotherapy.
- significant allergy to mugwort or pet animal allergens.
- uncontrolled asthma.
- upper airway disease.
- severe pulmonary disease.
- recent allergic reactions.
- immunosuppression.
- cardiovascular disease.
- malignant disease.
- use of ACE-blockers.
- other diseases or conditions rendering the treatment of anaphylactic reactions difficult.
Key Trial Info
Start Date :
February 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05297760
Start Date
February 10 2022
End Date
February 28 2025
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich
Zurich, Switzerland, 8091